Kyle A. Edgar

3.2k total citations
20 papers, 463 citations indexed

About

Kyle A. Edgar is a scholar working on Molecular Biology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kyle A. Edgar has authored 20 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 6 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kyle A. Edgar's work include PI3K/AKT/mTOR signaling in cancer (14 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Mosquito-borne diseases and control (3 papers). Kyle A. Edgar is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (14 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Mosquito-borne diseases and control (3 papers). Kyle A. Edgar collaborates with scholars based in United States, Italy and Singapore. Kyle A. Edgar's co-authors include Jeffrey J. Wallin, Marcia Belvin, Deepak Sampath, Wei Wei Prior, Lori S. Friedman, Leslie B. Lee, Fernando G. Noriega, Laurent Salphati, M A Wells and Megan Berry and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Cancer Research.

In The Last Decade

Kyle A. Edgar

20 papers receiving 439 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kyle A. Edgar United States	12	336	137	99	97	54	20	463
Barbara Hibner United States	6	391 1.2×	223 1.6×	64 0.6×	22 0.2×	68 1.3×	11	519
David Svilar United States	13	567 1.7×	180 1.3×	25 0.3×	71 0.7×	48 0.9×	14	663
James H. Ahn United States	7	397 1.2×	80 0.6×	29 0.3×	89 0.9×	18 0.3×	8	536
Kristen S. Hill United States	11	228 0.7×	110 0.8×	30 0.3×	21 0.2×	23 0.4×	24	361
Celia Sigua United States	9	738 2.2×	143 1.0×	22 0.2×	91 0.9×	37 0.7×	15	948
Katherine S. Pawelczak United States	13	816 2.4×	387 2.8×	64 0.6×	19 0.2×	33 0.6×	22	945
Candice L. Horn United States	6	457 1.4×	251 1.8×	55 0.6×	35 0.4×	45 0.8×	10	552
Francesca Alvarez‐Calderon United States	9	239 0.7×	65 0.5×	17 0.2×	62 0.6×	13 0.2×	12	438
Natalia G. Denissova United States	10	605 1.8×	246 1.8×	63 0.6×	24 0.2×	58 1.1×	10	761
Angen Liu United States	6	422 1.3×	95 0.7×	29 0.3×	21 0.2×	38 0.7×	6	515

Countries citing papers authored by Kyle A. Edgar

Since Specialization

Citations

This map shows the geographic impact of Kyle A. Edgar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle A. Edgar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle A. Edgar more than expected).

Fields of papers citing papers by Kyle A. Edgar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle A. Edgar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle A. Edgar. The network helps show where Kyle A. Edgar may publish in the future.

Co-authorship network of co-authors of Kyle A. Edgar

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle A. Edgar. A scholar is included among the top collaborators of Kyle A. Edgar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle A. Edgar. Kyle A. Edgar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Edgar, Kyle A., Rebecca Hong, Kyung Song, et al.. (2020). Abstract P3-11-23: GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models. Cancer Research. 80(4_Supplement). P3–11. 2 indexed citations

Gierke, Sarah, et al.. (2019). Effects of PI3K Inhibition on Afucosylated Antibody–Driven FcγRIIIa Events and Phospho-S6 Activity in NK Cells. The Journal of Immunology. 203(1). 137–147. 1 indexed citations

Hong, Rebecca, Kyle A. Edgar, Kai Song, et al.. (2018). Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. Cancer Research. 78(4_Supplement). PD4–14. 19 indexed citations

Edgar, Kyle A., Emily J. Hanan, Steven T. Staben, et al.. (2017). Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development. Cancer Research. 77(13_Supplement). 156–156. 11 indexed citations

Song, Kyung, Kyle A. Edgar, Donald S. Kirkpatrick, et al.. (2017). Abstract 146: The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models. Cancer Research. 77(13_Supplement). 146–146. 3 indexed citations

Hoeflich, Klaus P., Jane Guan, Kyle A. Edgar, et al.. (2016). The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase. Genes & Cancer. 7(3-4). 73–85. 15 indexed citations

Heffron, Timothy P., Chudi Ndubaku, Laurent Salphati, et al.. (2016). Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR. ACS Medicinal Chemistry Letters. 7(4). 351–356. 76 indexed citations

Gnad, Florian, Jeffrey J. Wallin, Kyle A. Edgar, et al.. (2016). Quantitative phosphoproteomic analysis of the PI3K‐regulated signaling network. PROTEOMICS. 16(14). 1992–1997. 4 indexed citations

Edgar, Kyle A., Kyung Bin Song, Stephen D. Schmidt, et al.. (2016). Abstract 370: The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action. Cancer Research. 76(14_Supplement). 370–370. 3 indexed citations

10.

Edgar, Kyle A., Lisa Crocker, Fang-You Chen, et al.. (2014). Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition. Genes & Cancer. 5(3-4). 113–126. 14 indexed citations

11.

Wallin, Jeffrey J., Jane Guan, Kyle A. Edgar, et al.. (2012). Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes. PLoS ONE. 7(5). e36402–e36402. 39 indexed citations

12.

Edgar, Kyle A., Jeffrey J. Wallin, Megan Berry, et al.. (2010). Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors. Cancer Research. 70(3). 1164–1172. 94 indexed citations

13.

Salphati, Laurent, Harvey Wong, Marcia Belvin, et al.. (2010). Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941. Drug Metabolism and Disposition. 38(9). 1436–1442. 63 indexed citations

14.

Wallin, Jeffrey J., Jane Guan, Wei Wei Prior, et al.. (2010). Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer. Science Translational Medicine. 2(48). 48ra66–48ra66. 46 indexed citations

15.

Wallin, Jeffrey J., Kyle A. Edgar, Jane Guan, Lori S. Friedman, & Marcia Belvin. (2009). Abstract #3392: Transient pAkt increase after chemo exposure predicts strength of synergy for combinations of the PI3K inhibitor GDC-0941 and chemotherapeutics. Cancer Research. 69. 3392–3392. 1 indexed citations

16.

Patel, Shanaya, Deepak Sampath, Marcia Belvin, et al.. (2008). 217 POSTER Pre-clinical evaluation of efficacy and PK/PD biomarkers of GDC-0941, a potent class 1 PI3K inhibitor. European Journal of Cancer Supplements. 6(12). 69–69. 2 indexed citations

17.

Noriega, Fernando G., et al.. (2002). Midgut exopeptidase activities in Aedes aegypti are induced by blood feeding. Journal of Insect Physiology. 48(2). 205–212. 37 indexed citations

18.

Noriega, Fernando G., et al.. (2001). Neuroendocrine factors affecting the steady-state levels of early trypsin mRNA in Aedes aegypti. Journal of Insect Physiology. 47(4-5). 515–522. 8 indexed citations

19.

Edgar, Kyle A., Fernando G. Noriega, Bryony C. Bonning, & M A Wells. (2000). Recombinant juvenile hormone esterase, an effective tool for modifying juvenile hormone‐dependent expression of the early trypsin gene in mosquitoes. Insect Molecular Biology. 9(1). 27–31. 14 indexed citations

20.

Coote, Peter J., M. Jones, Kyle A. Edgar, & Martin Cole. (1992). TPK gene products mediate cAMP-independent thermotolerance in Saccharomyces cerevisiae. Journal of General Microbiology. 138(12). 2551–2557. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact